AgomAb last raised $100.7M in its Later Stage VC (Series C) (Oct 2023).
- ·The complete investor list: 17 names
- ·Watch AgomAb: the Monday email on marks, rounds and moves
AgomAb funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2023 | Later Stage VC (Series C) | $100.7M | ▮ | ▮ |
Membership and data by Private Market View
AgomAb valuation
AgomAb's last known valuation is $416 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has AgomAb raised?
AgomAb has raised $334 million in total; 1 of its rounds is on record. The largest on record was a $101 million Series C in Oct 2023.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: CORXEL Pharmaceuticals ($475 million), Diagonal Therapeutics ($459 million) and Hemab Therapeutics Holdings ($387 million).
How AgomAb's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For AgomAb, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked about AgomAb
- What is AgomAb worth?
- AgomAb's last known valuation is $415.6M.
- How much has AgomAb raised?
- AgomAb has raised $334.0M in total funding across 1 recorded rounds.
- When did AgomAb last raise?
- AgomAb last raised in Oct 2023 (Later Stage VC (Series C)), raising $100.7M.